The European Commission and BioNTech-Pfizer reached a deal for the EU to purchase 200 million additional doses of BioNTech-Pfizer’s COVID-19 vaccine, with 100 million more as an option, doubling the doses that EU member states can purchase to 600 million.
The EU has already been rolling out the BioNTech-Pfizer vaccine. The additional doses will be available starting in the second quarter of 2021. This purchase will enable the EU to go beyond vaccinating its own population to supplying vaccines to neighboring countries.
Clinical trials found the Pfizer-BioNTech’s vaccine, which uses new messenger RNA (mRNA) technology, to be 95% effective. The vaccine was the first approved by the EU for use on December 21, 2020.